Price
10.47
+1.74%52W Range
Market Cap
₹203.39 Cr
Traded: ₹0.34 Cr (0.17%) 0.0x
Free Float: ₹89.29 Cr (0.38% of FF traded)
Volume · 60D trend
3.22 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -49.0% | -74.0% | -89.0% | -- | -78.0% | Stable |
| ROE | -1.0% | -4.0% | -6.0% | -- | -- | Decelerating |
| Return | -11.0% | -18.0% | -24.0% | -24.0% | -- | Stable |
| Profit | -- | -4.0% | +4.0% | -- | -9161.0% | Stable |
Quarterly Results
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 1 | 0 | 1 | 5 | 0 | 0 | 6 | 359 | 441 | 452 | 398 | 394 | 389 | 344 |
| Expenses | 28 | 59 | 2 | 0 | 6 | 0 | 0 | 6 | 319 | 393 | 410 | 371 | 359 | 371 | 343 |
| Operating Profit | -27 | -57 | -2 | 1 | -1 | 0 | 0 | -1 | 40 | 48 | 42 | 27 | 36 | 18 | 1 |
| OPM % | -6198.0% | -4437.0% | -- | 77.0% | -16.0% | -500.0% | -500.0% | -10.0% | 11.0% | 11.0% | 9.0% | 7.0% | 9.0% | 5.0% | 0.0% |
| Other Income | 3 | -24 | 35 | -176 | -62 | -130 | 8 | 7 | 1 | 1 | 0 | 11 | 0 | 18 | 13 |
| Interest | 0 | 6 | 30 | 0 | 0 | 0 | 0 | 0 | 20 | 24 | 25 | 21 | 18 | 20 | 17 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Profit Before Tax | -24 | -88 | 3 | -176 | -64 | -130 | 8 | 5 | 5 | 11 | 2 | 2 | 3 | 2 | -18 |
| Tax % | -37.0% | -22.0% | -339.0% | 0.0% | -1.0% | 0.0% | 2.0% | -2.0% | 40.0% | 95.0% | 36.0% | 38.0% | 41.0% | -145.0% | -47.0% |
| Net Profit | -15 | -68 | 14 | -176 | -63 | -130 | 8 | 6 | 3 | 1 | 2 | 1 | 2 | 4 | -9 |
| Exceptional Items | 0 | -31 | 35 | -176 | -63 | -130 | 8 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | -0.8 | -3.5 | 0.6 | -7.8 | -2.8 | -5.8 | 0.3 | 0.3 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.2 | -0.4 |
| Sales Growth (YoY) | -100.0% | -- | -- | -83.3% | -98.6% | -100.0% | -100.0% | -98.5% | -8.9% | 13.4% | 31.4% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -100.0% | -- | -100.0% | -80.0% | -- | -- | -100.0% | -98.3% | -18.6% | -2.4% | 13.6% | 1.0% | 1.3% | 13.1% | -- |
| OP Growth (YoY) | -2600.0% | -- | -- | 200.0% | -102.5% | -100.0% | -100.0% | -103.7% | 11.1% | 166.7% | 4100.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 52.6% | -2750.0% | -300.0% | 200.0% | -- | -- | 100.0% | -102.5% | -16.7% | 14.3% | 55.6% | -25.0% | 100.0% | 1700.0% | -- |
| Profit Growth (YoY) | -2212.0% | -33727.0% | -9026.0% | 230.0% | -123.0% | -119.0% | -85.0% | -123.0% | 63.0% | -84.0% | 117.0% | 105.0% | -53.0% | -68.0% | -195.0% |
| EPS Growth (YoY) | 72.0% | 39.7% | 82.9% | -3240.0% | -2269.2% | -19433.3% | 400.0% | 400.0% | 62.5% | -81.3% | 117.1% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 77.4% | -646.9% | 108.2% | -178.4% | 51.4% | -1757.1% | 40.0% | 92.3% | 333.3% | -57.1% | 40.0% | -37.5% | -50.0% | 139.0% | -- |
| OP Margin | -- | -5700.0% | -- | 100.0% | -20.0% | -- | -- | -16.7% | 11.1% | 10.9% | 9.3% | 6.8% | 9.1% | 4.6% | 0.3% |
| Net Margin | -- | -6800.0% | -- | -17600.0% | -1260.0% | -- | -- | 100.0% | 0.8% | 0.2% | 0.4% | 0.3% | 0.5% | 1.0% | -2.6% |
| Material Cost % | 5.0% | 0.0% | -- | 0.0% | 67.0% | 0.0% | 0.0% | 68.0% | 66.0% | 70.0% | 72.0% | 72.0% | 71.0% | 75.0% | 78.6% |
| Employee Cost % | 241.0% | 98.0% | -- | 3.0% | 13.0% | 200.0% | 300.0% | 12.0% | 7.0% | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% | 5.7% |
| P/S | 101.70 | 30.53 | 0.55 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 0.35 | 0.37 | 0.34 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please find attached herewith letter sent to the members pursuant to Regulation 36(1)(b)of the SEBI (LODR) Regulations, 2015.
Please find attached herewith newspaper publication of notice of 31st Annual General Meeting, e-voting, book closure & other information.
Pursuant to Regulations 30 and 34 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copy of Annual ....
Please find attached herewith Notice of 31st AGM for the Financial Year 2025-26 is scheduled to be held on Friday, September 18, 2026
Please find attached herewith newspaper publication of notice to the shareholders regarding 31st AGM of the Company to be held on Friday, September 18, 2026, through Video Conferencing ....
Please find attached herewith copies of newspaper publication of financial results ended on June 30, 2026.
Please find attached herewith letter of change in corporate office of the Company
AGM to be held on September 18, 2026 and book closure date for the same is from September 12, 2026 to September 18, 2026(both days inclusive). The Cut-off date, to ascertain the eligibility ....
We wish to inform you that the board of directors of Nectar Lifesciences Limited ('Company') in their meeting held on August 14, 2026, have, inter-alia, noted, decided and approved the ....
Please find attached herewith the financial results for the quarter ended on June 30, 2026.
Nectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Please find attached herewith letter of Resignation of Non-Executive Non-Independent Director of the Nectar Lifesciences Limited
Please find attached herewith letter w.r.t.: Update on Slump Sale
We wish to inform you that the board of directors of Nectar Lifesciences Limited (''Company'') has change the registered office of the Company
Please find attached herewith the certificate as per caption regulations
Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Please find attached herewith copy of newspaper publication as per Section 124(6) of Companies Act, 2013
Please find attached herewith the copy of newspapers for publication of financial results of the Company for the quarter and financial year ended on March 31, 2026
Financial Results for the Year 2025-26
Nectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited Financial Results ....
Please find attached herewith disclosures under Regulation 30 of the Securities and Exchange of Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015
Please find attached herewith letter w.r.t.: Update on Slump Sale
Please find attached herewith Annual Secretarial Compliance Report for the year ended on March 31, 2026
Please find attachment.
Please find attached herewith the certificate as per captioned regulations
Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Please find attached herewith disclosures under Regulation 30 of the Securities and Exchange of Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015
Please find attached herewith the Minutes of the Ordinary and Special Resolutions passed by way of Postal Ballot by the Members of the Company as set out in the Postal Ballot Notice dated ....
Please find attached herewith Intimation of inter-corporate loan agreement with Avensis Exports Private Limited, a Wholly Owned Subsidiary of the Nectar Lifesciences Limited
Please find attached herewith disclosures under Regulation 30 of the Securities and Exchange of Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015
Update on Acquisition of 100% paid- up equity share capital of Avensis Exports Private Limited (CIN: U51109DL2007PTC169484)
Updation of disclosures by Nectar Lifesciences Limited as per point no. 1 of its letter no. NLL/CS/2026- 659 dated March 02, 2026.
We would like to inform you that the Board of the Company at its meeting held on 02.03.2026 has considered and approved the acquisition of 100% paid-up equity share capital of Avensis Exports ....
We wish to inform you that the board of directors of Nectar Lifesciences Limited ('Company') in their meeting held on Monday, March 02, 2026, have, inter-alia, noted, decided and approved ....
Nectar Lifesciences Limited has informed the Exchange regarding ''''Results of Postal Ballot ''''.
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(3) and 4(c) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for
Please find attached herewith copy of newspaper publication about dispatch/ mailing of Postal Ballot Notice
Please find enclosed the Postal Ballot Notice together with the Explanatory Statement thereto, seeking approval of the Members for Appointment of Mr. Sushil Kapoor as a Director of the ....
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanjiv Goyal & Others
The Exchange has received the disclosure under Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanjiv Goyal & Others
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanjiv Goyal & Others
Please find attached herewith newspaper copy of Financial Results of the Company for the quarter and nine months ended on December 31, 2025.
We wish to inform you that the board of directors of Nectar Lifesciences Limited ('Company') in their meeting held on Friday, January 23, 2026, have, inter-alia, noted, decided and approved ....
Please find attached herewith Results For Quarter And Nine months Ended December 31, 2025.
Please find attached herewith the letter of Completion of extinguishment of equity shares of the Company
Nectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Master Capital Services Ltd ("Manager to the Buyback") has submitted to BSE a copy of Post Buyback Public Announcement for the attention of equity shareholders / beneficial owners of equity ....
Newspaper Publication of post Buyback Public Announcement
Please find attached herewith the certificate as per captioned regulations.
Newspaper advertisement pertaining to dispatch of Letter of Offer
Annual Reports
14Credit Ratings
6Held by ETFs
1 ETFs hold neclife · sorted by weight
Held by Mutual Funds
1 schemes hold neclife · sorted by weight